Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Healthcare Psychedelics
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:MNMD)

MindMed Appoints Matt Wiley as Chief Commercial Officer

Business Wire 12 hours ago

MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates

Business Wire 11 days ago

MindMed to Present at Leerink's Global Healthcare Conference 2025

Business Wire 13 days ago

MindMed to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

Business Wire February 20, 2025

MindMed to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Business Wire February 4, 2025

MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder

Business Wire January 30, 2025

MindMed to Be Added to the Nasdaq Biotechnology Index

Business Wire December 19, 2024

MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)

Business Wire December 16, 2024

MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress

Business Wire December 11, 2024
View More News ››

Opinion & Analysis (NDAQ:MNMD)

Buzz on the Bullboards: Tracking the Big Movers of 2020

Stockhouse Editorial December 17, 2020

Broadway Gold ramps up exploration at Madison Mine

The Gold Report March 2, 2017
View More Opinion ››

Bullboard Posts (NDAQ:MNMD)

MindMed to Present at the Oppenheimer 35th Annual Healthcare

News; $MNMD MindMed to Present at the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceMind Medicine (MindMed) Inc. (NASDAQ...
whytestocks - February 4, 2025

A Recap of the Highlights for the Psychedelics Industry in 2

NEWS: $MNMD A Recap of the Highlights for the Psychedelics Industry in 2024The psychedelics industry experienced various peaks and pits...
whytestocks - January 6, 2025

MindMed Reports Third Quarter 2024 Financial Results and Bus

News; $MNMD MindMed Reports Third Quarter 2024 Financial Results and Business Updates--On track to initiate the Phase 3 Voyage study of...
whytestocks - November 7, 2024

RE:RE:RE:Stock Price Pressure

49.12% % of Shares Held by Institutions 50.47% % of Float Held by Institutions 161 Number of Institutions Holding Shares % was 5%,...
Robert1999 - June 6, 2024

RE:Stock Price Pressure

This doesn't look great. PTSD treatment was kind of MM's thing. https://www.forbes.com/sites/roberthart/2024/06/05/psychedelic...
Starkicker - June 6, 2024

RE:RE:Stock Price Pressure

Further searching found this on seeking alpha https://seekingalpha.com/news/4113189-rbc-recommends-buying-mindmed-amid-psychedelic-stocks...
sollmg - June 5, 2024
View more Bullboard ››

Calima Energy Ltd

Calima Energy Ltd

Calima Energy Limited is an Australia-based production-focused energy company. The Company is engaged in the exploration and ...
View More »